Mika Kakefuda Derynck

Mika is the Chief Medical Officer at Amunix Pharmaceuticals and has over 25 years of experience in drug development and expertise in oncology, covering multiple therapeutic modalities, tumor types, and development phases. Previously, Mika worked at Genentech, most recently as Global Head for Cancer Immunotherapy, GI/GU Cancers, Angiogenesis Franchises, and China Oncology Development. Previous to that she was Global Head of the Breast Cancer Franchise for Development. While at Genentech, she oversaw the approval or global development of more than a dozen drugs. She was previously a Senior Group Medical Director of Exploratory Clinical Development at Genentech, leading the development of several early-stage programs.

Prior to joining Genentech, Mika was an Assistant Clinical Professor in the Department of Cellular and Molecular Oncology and Division of Hematology/Oncology at the University of California, San Francisco.

Mika received an M.D. from Boston University School of Medicine and a B.A. in Biology from Boston University. She completed an Internal Medicine residency at Johns Hopkins Hospital and a fellowship in Medical Oncology at the University of California, San Francisco.